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It has been suggested that the DGCR2 gene plays a role in the pathogenesis of 22q11.2 deletion syndrome.
To analyze its function, we used our Dgcr2-knock-out/EGFP-knock-in mice (Dgcr2-KO mice). At 20-26
weeks of age, approximately 20% of Dgcr2-KO mice showed gait abnormalities with trembling and dif-
ﬁculty in balancing. Footprint test revealed awkward movements in Dgcr2-KO mice soon after they were
placed on the ﬂoor. Once they started walking, their stride lengths were not different from wild-type
mice. In short-term open ﬁeld test, Dgcr2-KO mice travelled a signiﬁcantly shorter distance and walked
more slowly than wild-type mice during the initial 5 min after being placed in a new environment. In
long-term open ﬁeld test, Dgcr2-KO mice exhibited reduced cage activity compared to wild-type mice on
the ﬁrst day, but not on later days. Dgcr2-KO mice showed reduced latency to fall in the rotarod test, and
the latency was not improved in the 3-day test. Histology revealed sparseness of cerebellar Purkinje cells
in Dgcr2-KO mice. Our results suggest that Dgcr2 plays a role in motor control related to Purkinje cell
function and that the deﬁciency of DGCR2 contributes at least to some of the symptoms of patients of
22q11.2 deletion syndrome.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Previously, we isolated several cDNA clones whose expression
was altered in murine primary cultures of embryonic neuron and
brain upon stimulation with pentylenetetrazole, a seizure-indu-
cing compound [1]. One of the downregulated genes, Dgcr2 (Sez12)
[2], is a mouse homolog of human DGCR2 gene that is located in
the human chromosome 22q11.2 region and encodes a C-type
lectin-like transmembrane protein. It is known that heterologous
microdeletion in chromosome 22q11.2 causes a syndrome termed
22q11.2 deletion syndrome (22q11.2 DS) [3]. 22q11.2 DS includes
DiGeorge syndrome, conotruncal anomaly face syndrome, and
velocardiofacial syndrome. Congenital heart disease and immune
disorder are typically seen at birth in patients of 22q11.2 DS. Also
common in 22q11.2 DS is growth retardation including delayed
motor development [4,5], facial dysmorphia, palatal anomalies,
abnormal cerebellar morphology [6,7], and early feeding problems
[8,9]. Other characteristic signs and symptoms of 22q11.2 DSr B.V. This is an open access article
otein
ajiwara).include psychiatric disorders with abnormal behavior, autistic
spectrum disorders [10], and unprovoked seizures [11,12].
Individuals carrying the 22q11.2 microdeletion are also at risk
of other psychiatric diseases, including anxiety and mood disorder
[13,14]. Recent evidence has indicated a relationship between the
genes within the 22q11.2 region and the clinical features of
22q11.2 DS, such as schizophrenia [10,13-15].
Our previous study in mutant mice suggested that the deletion
of the gene for catechol-O-methyltransferase, rather than Dgcr2, is
associated with an increased risk of schizophrenia in individuals of
22q11.2 DS [16]. However, it remains unclear which of the genes
involved in the 22q11.2 microdeletion are responsible for other
clinical features of 22q11.2 DS. Based on the previous ﬁndings that
the human DCGR2 is one of the genes involved in the microdele-
tion of 22q11.2 DS and the expression of Dcgr2, the mouse
homolog of the human DCGR2, is affected by a seizure-provoking
agent in cultured cells [2], we have hypothesized that the loss of
DGCR2 gene is involved in some of the neurological dysfunctions
underlying the clinical manifestations of 22q11.2 DS, a product of
complex genetic interactions.
To investigate the function of the Dgcr2 gene products, we have
recently generated Dgcr2-knock-out/EGFP-knock-in (Dgcr2-KO)under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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motorless EGFP gene inserted into the upstream of the initiation
codon of Dgcr2 to visualize the pattern of Dgcr2 expression.
In the present study, we examined the motor performance of
Dgcr2-KO mice using footprint analysis, open ﬁeld tests and ro-
tarod test, and compared the results to those in wild-type mice to
test our hypothesis that the symptoms of 22q11.2 DS patients in-
volve the deﬁciency of DGCR2 gene.2. Materials and methods
2.1. Animals
Generation of Dgcr2-KO mice has been described [16]. Mice
were crossed with C57BL/6 strain for at least 8 generations.
Homozygous Dgcr2-KO and wild-type mice were obtained by
mating heterozygous Dgcr2-KO mice and were identiﬁed by gen-
otyping using PCR [16].
This study was in accordance with Guidelines for the Care and
Use of Animals for Scientiﬁc Purposes at Tokai University and
approved by the Institutional Review Board of Tokai University
School of Medicine (Permit number: 151031).
2.2. Footprint analysis
The rear feet of mice were coated with non-toxic black ink, and
each animal was allowed to walk on a 29.7 cm42 cm absorbent
paper. Stride lengths of the right and left rear feet were measured
during the ﬁrst 3–8 steps by using the footprints and movies.
2.3. Open ﬁeld tests
Two types of open ﬁeld test were conducted. For short-term
open ﬁeld test, each mouse was placed at a corner of a plastic
60 cm60 cm40 cm box, and the movement was recorded with
a CCD camera from above for the initial 5 min. A 30 cm30 cm
square area at the center of the ﬂoor was designated as “the center
zone”. A video behavior analysis software, Smart (Panlab Co.,
Barcelona, Spain), was used to measure horizontal travelled dis-
tance, the numbers of entries from the outer zone to the center
zone and from the center zone to the outer zone, resting time and
walking speed for each mouse in the ﬁrst 5minutes after the an-
imal was placed on the ﬂoor. Resting time was deﬁned as the time
when the mouse was moving slower than 4 cm/s. Walking speed
was calculated after excluding resting time. For long-term open
ﬁeld test, each mouse was placed in a transparent acrylic
37 cm24 cm27 cm box, and cage activity and the cumulative
rearing frequency were recorded with an infrared sensor (SU-
PERMEX, MUROMACHI Kikai Co., Tokyo, Japan) under a 12-h light/
12-h dark condition. Mice were placed in the box during the light
phase. The ﬁrst light (3 h) and dark (12 h) phases, which generally
are regarded as a period of acclimatization or searching, were
designated as Day 0. Cage activity on Day 0 was expressed in
counts per minute, and that on Day 1–3 were determined sepa-
rately for the light and dark phases and expressed in an arbitrary
unit. A water bottle and a food container were equipped in the
box. The test was performed for four consecutive days for each
animal.
2.4. Rotarod test
A rotarod treadmill (MUROMACHI Kikai Co., Tokyo, Japan)
consisting of a gridded plastic rod (5 cm in diameter) was used.
Mice were given one day to become acclimatized with the rotarod
apparatus. On the testing day, a mouse was placed on the rodrotating at 5 rpm, and the latency to fall was measured. Each
mouse was given three trials per day for a maximum of 300 s in
each trial. The test was performed on three consecutive days. The
test was performed at 10 rpm as well.
2.5. Hanging wire grip test
A standard wire cage lid was used. The perimeter of the cage lid
was wrapped with aluminum foils to prevent the mouse from
walking off the cage lid. Each mouse was placed on the wire cage
lid, and the lid was turned upside down at a height of approxi-
mately 20 cm. We measured the time until the mouse fell from the
cage lid. A 60-s cutoff time was used.
2.6. Blood calcium concentration
Mice at 12–16 weeks of age were euthanized by intraperitoneal
administration of 74 mg/kg body weight pentobarbital, and blood
was sampled via cardiac puncture. To measure blood calcium
concentrations, Calcium E-HA test (Wako Pure Chemical Ltd.,
Osaka, Japan) was used. This method is based on the formation of a
complex between serum calcium and methyl xylenol blue under
alkaline conditions (pH 12).
2.7. Immunohistochemistry
Mice were deeply anesthetized and perfused with 3% heparin
in phosphate buffered saline (PBS), followed by 4% paraf-
ormaldehyde. A sagittal half of the cerebellum was taken, ﬁxed in
4% paraformaldehyde for 16 h at 4 °C and embedded in parafﬁn,
and serial 5-mm sections were prepared. Prior to immunostaining,
the sections were treated with 3% hydrogen peroxide and then
with 10% normal goat serum in PBS for 1 h at room temperature.
The sections were incubated with rabbit anti-GFP antibody (ab290,
Abcam, Cambridge, UK; at 1:500 dilution) overnight at 4 °C. After
washing with PBS, the sections were incubated with horseradish
peroxidase-labeled goat anti-rabbit antibody (ab6721, Abcam; at
1:1000 dilution) for 60 minutes at room temperature. The ex-
pression of EGFP was visualized using 3,3,-diaminobenzidine tet-
rahydrochloride as chromogen. Sections of wild-type cerebellum
were used as negative controls. The sections were photographed
with Zeiss Imager A2 microscope (Zeiss, Germany). Frozen 10-mm
sections of the cerebellum were also prepared and stained with
rabbit anti-ß III tubulin antibody (D71G9, Cell Signaling Technol-
ogy, Danvers, Massachusetts, USA; at 1:200 dilution) and Alexa
Flour 594-labeled goat anti-rabbit antibody (ab150080, Abcam; at
1:500 dilution). Sections were photographed by confocal micro-
scopy with Zeiss LSM 700 (Zeiss, Germany).
2.8. Statistical analysis
Values were expressed as the mean7SEM. Differences were
tested by t-test, ANOVA or post-hoc Scheffe's test as appropriate.
All statistical analyses were done by using IBM SPSS Statistics
version 22 (IBM Japan Co., Tokyo, Japan). A p-valueo0.05 was
considered signiﬁcant.3. Results
3.1. Gait
At 20-26 weeks of age, some Dgcr2-KO mice exhibited apparent
gait disturbance with slight trembling and difﬁculty in keeping
balance while walking. Two of the ten representative Dgcr2-KO
mice we examined showed awkward and uneasy movement with
Fig. 1. Footprint test. A representative of abnormal footprint patterns seen in Dgcr2-KO mice (A). As can be seen also in Supplementary movie 1, apparent gait abnormalities
were observed after the mice started walking in some but not all Dgcr2-KO mice. A representative of normal footprint patters seen in other Dgcr2-KO mice
(B) indistinguishable from that seen in wild-type mice (C). These mice were 22-24 weeks old and correspond to the mice in Supplementary movie 1–3. L1 and R1 indicate the
starting point of the left foot and right rear foot, respectively.
Table 1
Undistinguishable ﬁndings between wild-type and Dgcr2-KO mice.
WT KO p-Value
Stride length (mm)
Left foot 62.572.3 53.474.7 0.13
Right foot 61.171.1 54.573.7 0.16
n 8 10
Blood calcium
concentration (mg/dl) 7.970.3 8.370.3 0.43
n 6 6
Hanging wire
Grip test (sec) 60.070.0 56.672.5 0.36
n 9 18
Values are mean7SEM. Differences between the groups were tested by t-test.
Abbreviations are: WT, wild-type mice; KO, Dgcr2-KO mice.
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footprint analysis. Fig. 1A shows gait abnormality of Dgcr2-KO
mice. This characteristic behavior lasted for a few tens of seconds
and was repeatedly observed. Once Dgcr2-KO mice started walk-
ing, they walked more slowly than wild-type mice with trembling
as shown in Supplementary movie 1. The remaining eight Dgcr2-
KO mice showed normal gaits (Fig. 1B and Supplementary movie
2) similar to that of wild-type mice (Fig. 1C and Supplementary
movie 3). We measured the mean stride lengths of the right and
left feet in all ten Dgcr2-KO mice including the two exhibiting
abnormal gaits and in eight wild-type mice. The mean stride
length was not different between Dgcr2-KO and wild-type mice
(Table 1).Supplementary material related to this article can be found
online at 10.1016/j.bbrep.2015.11.015.
3.2. Open ﬁeld tests
Dgcr2-KO mice showed abnormal gaits right after being placed
on the ﬂoor, whereas their stride lengths were comparable to
those of wild-type mice. To investigate in more detail about the
locomotor activity of Dgcr2-KO mice, we employed two types of
open ﬁeld test. In short-term open ﬁeld test, the travelled distance
of Dgcr2-KO mice was signiﬁcantly shorter than that of wild-type
mice (po0.001) (Fig. 2A). The numbers of entries from the outer
zone to the center zone and from the center zone to the outer zone
were also signiﬁcantly reduced in Dgcr2-KO mice (10.072.0 and
9.871.9, respectively) compared to wild-type mice (15.471.2 and
15.471.2, respectively; po0.05). Resting time was signiﬁcantly
longer in Dgcr2-KO than in wild-type mice (Fig. 2B). Walking
speed was signiﬁcantly slower in Dgcr2-KO mice than in wild-type
mice through the entire ﬁve minutes of observation (Fig. 2C). Thus,
locomotor activity was impaired in Dgcr2-KO mice not only for
several tens of seconds after they were placed on the ﬂoor as seen
in the footprint test but also for at least ﬁve minutes or more.
Next, long-term open ﬁeld test was conducted to examine
whether such locomotor activity impairments persist for a longer
time. In long-term open ﬁeld test, the cage activity on Day 0 was
signiﬁcantly reduced in Dgcr2-KO mice compared to that in wild-
type mice (po0.05; Fig. 2D). However, their cage activities on Day
1–3 were comparable for both the dark and the light phases
(Fig. 2D). No signiﬁcant difference was found in the rearing fre-
quency between Dgcr2-KO and wild-type mice (Day 0, 3.070.4 in
wild-type and 2.070.3 in KO mice; Day 1–3 light phase, 0.470.0
in wild-type and 0.470.2 in KO mice; Day 1–3 dark phase,
2.570.5 in wild-type and 1.970.8 in KO mice). These results
Fig. 2. General locomotor activity in open ﬁeld tests.Travelled distance (A), resting time (B) and walking speed (C) in the ﬁrst ﬁve minutes after the animals were placed in
the box for short-term open ﬁeld test were compared between Dgcr2-KO (KO; ﬁlled bars) and wild-type mice (WT; open bars). Dgcr2-KO mice showed lower locomotor
activity (** po0.001 by t-test) and slower motion than wild-type mice (po0.001 by ANOVA, ** po0.001 by post-hoc Scheffe’s test). The numbers of analyzed animals were
10 and 15 for wild-type and Dgcr2-KO mice, respectively. Cage activity (D) in long-term open ﬁeld test was compared between Dgcr2-KO and wild-type mice. Cage activities
on Day 1 to 3 were in an arbitrary unit (AU) and averaged. The numbers of analyzed animals were 6 and 10 for wild-type and Dgcr2-KO mice, respectively. Cage activity on
Day 0 was signiﬁcantly lower in Dgcr2-KO mice than in wild-type mice (* po0.05 by t-test). Error bars indicate SEM.
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KO mice were temporally limited to when they were placed in a
new environment.
3.3. Rotarod test
To examine if Dgcr2-KO mice have abnormalities not only inFig. 3. Motor coordination and motor learning in rotarod test. The latencies on the rod r
circles) and wild-type mice (open circles). Each trial was performed with the cutoff perio
group; po0.001 by ANOVA; ** po0.001 by post-hoc Scheffe's test). Error bars indicatelocomotor activity but also in forced motor activity or motor
learning, we used the rotarod test. Our results showed that the
latency to fall was signiﬁcantly shorter in Dgcr2-KO mice than in
wild-type mice at both 5 and 10 rpm (po0.001; Fig. 3). In addi-
tion, the latency at 5 rpm became longer in wild-type mice during
the 3-day test, whereas no signiﬁcant improvement was found in
Dgcr2-KO mice (Fig. 3).otating at 5 rpm (A) and 10 rpm (B) were compared between Dgcr2-KO mice (ﬁlled
d of 300 s. Dgcr2-KO mice showed a shorter latency than wild-type mice (n ¼ 8 per
SEM.
Fig. 4. Morphology of Purkinje cells. EGFP immunostaining of the cerebellum from wild-type (A) and Dgcr2-KO mice (B). Knocked-in EGFP was strongly expressed in
Purkinje cells of Dgcr2-KO mice. Hematoxylin and eosin staining of the cerebellum fromwild-type (C and E) and Dgcr2-KO mice (D and F). Immunostaining of the cerebellum
from wild-type (G) and Dgcr2-KO mice (H) using anti βIII tubulin antibody. The number of Purkinje cells appeared reduced in Dgcr2-KO mice compared to that in wild-type
mice. The scale bars represent 20 μm in the insets and 100 μm in others.
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Since 22q11.2 DS patients manifest tremor caused by neuro-
muscular abnormality and/or hypocalcemia [17–19], we conducted
the hanging wire grip test and measured blood calcium con-
centrations in Dgcr2-KO and wild-type mice. No signiﬁcant dif-
ferences were found in the hanging wire grip test or blood calcium
concentrations between Dgcr2-KO and wild-type mice (Table 1).
3.5. Morphology of Cerebellar Purkinje cells
The expression of the knocked-in EGFP was intense in cere-
bellar Purkinje cells and relatively weak in the cerebellar mole-
cular layer in Dgcr2-KO mice (Fig. 4A and B), suggesting that Dgcr2
is strongly expressed in Purkinje cells. Hematoxylin and eosin
staining showed sparseness of cerebellar Purkinje cells in Dgcr2-
KO mice (Fig. 4D and F) compared to the distribution of Purkinje
cells in wild-type mice (Fig. 4C and E). Anti-ß III tubulin antibody
staining also showed Purkinje cell reduction in Dgcr2-KO mice
(Fig. 4G and H). These results suggest that Dgcr2 contributes to the
establishment of Purkinje cells.4. Discussion
In this study, we demonstrated that Dgcr2-KO mice exhibited
reduced general locomotor activity in the open ﬁeld tests and poor
motor coordination in the rotarod test. We previously demon-
strated ubiquitous expression of Dgcr2 including muscle cells in
mice [2]. Our present results further suggested that Dgcr2 ex-
pression in the brain, particularly the expression in cerebellar
Purkinje cells, plays a role in regulating locomotor activity and
coordination. This notion arises because a loss of Purkinje cells was
observed in Dgcr2-KO mice whereas no abnormalities were found
in the morphology of muscle cells (data not shown) or in the
strength of the muscles (the hanging wire grip test; Table 1).
Cerebellar hypoplasia was found in some but not all patients
with a 22q11.2 deletion [7]. In addition, it was reported that young
patients with a 22q11.2 deletion including DGCR2 gene showed
signiﬁcant motor deﬁcits [4]. In our study, Dgcr2-KO mice ex-
hibited deﬁcits in locomotor activity and motor coordination,
suggesting that motor deﬁcits observed in patients of 22q11.2 DS
are caused by the loss of DGCR2 gene, while Dgcr2-KO mice had no
gross morphological abnormalities such as hypoplasia in the brain.
Such a difference is probably caused by the fact that the portion of
the genome deleted in 22q11.2 DS contains multiple genes, which
usually results in severer phenotypes than a single gene deletion.
We demonstrated that the EGFP knocked-in under the pro-
motor of Dgcr2 was strongly expressed in Purkinje cells (Fig. 4B). It
is likely that a C-type lectin-like transmembrane protein, the
product of Dgcr2 gene, is essential for establishing or maintaining
functional Purkinje cells. A previous study revealed disrupted
migration of parvalbumin-positive interneurons in the cortex in
LgDel mouse, a model of 22q11.2 DS having a loss of Dgcr2 gene
locus [20]. Although a partial loss of Purkinje cells was found and
the existing Purkinje cells appeared morphologically normal in
Dgcr2-KO mice (Fig. 4), it is possible that those Purkinje cells did
not function normally. Further studies are required to elucidate
how Dgcr2 contributes to the establishment and maintenance of
functional Purkinje cells.
In footprint analysis, approximately 20% of Dgcr2-KO mice
showed gait abnormality and the remaining 80% of KO mice
showed normal gaits (Fig. 1 and Supplementary movies 1,2,3). Yet,
general locomotor activity and motor coordination were sig-
niﬁcantly impaired in all of Dgcr2-KO mice. In addition, reduced
locomotor activity appeared mainly after Dgcr2-KO mice wereplaced in a new environment, whereas their cage activity in-
creased over time, reaching a level comparable to that in wild-type
mice in three days (Fig. 2D). These ﬁndings can explain why our
recent study found the behavior of Dgcr2-KO mice indistinguish-
able from that of wild-type mice [16]. To date, a loss of Purkinje
cells has been reported in a number of spontaneous mutant mice
and gene-manipulated mice [21]. Even when a large number of
Purkinje cells were lost, as seen in lurcher and pcdmice, a diversity
of impairments in motor coordination and ataxic behavior were
observed [22–24]. The low penetration of the effects of a loss of
Dgcr2 gene and the temporally-limited impairment of locomotor
activity observed in Dgcr2-KO mice might reﬂect the partial loss of
Purkinje cells resulting in mosaic dysfunction of the cerebellum or
regional speciﬁcity of Dgcr2 deﬁciency.
22q11.2 DS is known as a hemizygous deletion syndrome [3].
Patients with this syndrome manifest not only motor deﬁcits but
idiopathic seizure, attention deﬁcit, and anxiety [5,6,15]. Such
characteristic symptoms associated with 22q11.2 DS may require
functional defects of other genes within 22q11.2 than DGCR2.
However, we cannot exclude the possibility that DGCR2 deﬁciency
is related to emotional and social abnormalities frequently ob-
served in patients of this syndrome because abnormal locomotor
activity of Dgcr2-KO mice manifested itself only when the mice
were placed in a new environment and, thus, is temporally
limited.
In summary, Dgcr2-KO mice showed temporally-limited deﬁ-
cits in locomotor activity, impaired motor coordination and motor
learning, and sparseness of cerebellar Purkinje cells. Our results
provide a clue to therapeutic strategies for diseases caused by
complex genetic interactions, such as 22q11.2 DS. Utilizing com-
bination of multiple animal models will help understand a number
of human diseases.Acknowledgments
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